Abstract

COVID-19 causes immune perturbations which may persist long-term, and patients frequently report ongoing symptoms for months after recovery. We assessed immune activation at 3-12 months post hospital admission in 187 samples from 63 patients with mild, moderate or severe disease and investigated whether it associates with long COVID. At 3 months, patients with severe disease displayed persistent activation of CD4+ and CD8+ T-cells, based on expression of HLA-DR, CD38, Ki67 and granzyme B, and elevated plasma levels of IL-4, IL-7, IL-17 and TNF-α compared to mild and/or moderate patients. Plasma from severe patients at 3 months caused T-cells from healthy donors to upregulate IL-15Rα, suggesting that plasma factors in severe patients may increase T-cell responsiveness to IL-15-driven bystander activation. Patients with severe disease reported a higher number of long COVID symptoms which did not however, correlate with cellular immune activation/pro-inflammatory cytokines after adjusting for age, sex and disease severity. Our data suggests that long COVID and persistent immune activation may correlate independently with severe disease.

Data availability

All data generated or analysed during this study are included in the manuscript files or supplementary files. Raw file (FCS files) for all flow cytometry data have been deposited in the FlowRepository, the link for access to the data is provided in the Material and Methods, Flow cytometry data analysis section.The code script and data for the analysis in Figure 6 are publicly available here: https://github.com/gushamilton/discover_long_covid. The link is provided in the Material and Methods, statistical analysis section.

The following data sets were generated

Article and author information

Author details

  1. Marianna Santopaolo

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Michaela Gregorova

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1605-0558
  3. Fergus Hamilton

    Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. David Arnold

    Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Anna Long

    Diabetes and Metabolism, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Aurora Lacey

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Alice Halliday

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Holly Baum

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1311-6446
  9. Kristy Hamilton

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Rachel Milligan

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Elizabeth Oliver

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1211-1942
  12. Olivia Pearce

    Diabetes and Metabolism, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. Lea Knezevic

    Bristol Veterinary School, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  14. Begonia Morales Aza

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  15. Alice Milne

    Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  16. Emily Milodowski

    Bristol Veterinary School, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  17. Eben Jones

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  18. Rajeka Lazarus

    University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  19. Anu Goenka

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  20. Adam Finn

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  21. Nicholas Maskell

    Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  22. Andrew D Davidson

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1136-4008
  23. Kathleen Gillespie

    Diabetes and Metabolism, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  24. Linda Wooldridge

    Bristol Veterinary School, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6213-347X
  25. Laura Rivino

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    For correspondence
    laura.rivino@bristol.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6213-9794

Funding

Wellcome Trust (Elizabeth Blackwell Institute (EBI) with funding from the University's alumni and friends)

  • Anu Goenka
  • Linda Wooldridge
  • Laura Rivino

Southmead Hospital Charity (DISCOVER)

  • Fergus Hamilton
  • David Arnold
  • Laura Rivino

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Information regarding our ethics approval and consent process is provided in the Materials and Methods section and copied below.Patients hospitalized with COVID-19 ({greater than or equal to}18 years of age) were recruited between 30th March and 3rd June 2020 into the observational study DIagnostic and Severity markers of COVID-19 to Enable Rapid triage (DISCOVER), a single-centre prospective study based in Bristol (UK). Research Ethics Committee (REC) approval: REC:20/YH/1021. Survivors were invited at 3, 8 and 12 months post admission to attend outpatient follow up clinics for a systematic clinical assessment (Arnold et al 2020). For those patients attending a face-to-face follow-up, consent was taken to collect samples for research purposes (blood for PBMC isolation, plasma and serum). When available serum collected from patients at admission was made available to the research team.

Copyright

© 2023, Santopaolo et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,127
    views
  • 459
    downloads
  • 25
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marianna Santopaolo
  2. Michaela Gregorova
  3. Fergus Hamilton
  4. David Arnold
  5. Anna Long
  6. Aurora Lacey
  7. Alice Halliday
  8. Holly Baum
  9. Kristy Hamilton
  10. Rachel Milligan
  11. Elizabeth Oliver
  12. Olivia Pearce
  13. Lea Knezevic
  14. Begonia Morales Aza
  15. Alice Milne
  16. Emily Milodowski
  17. Eben Jones
  18. Rajeka Lazarus
  19. Anu Goenka
  20. Adam Finn
  21. Nicholas Maskell
  22. Andrew D Davidson
  23. Kathleen Gillespie
  24. Linda Wooldridge
  25. Laura Rivino
(2023)
Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months
eLife 12:e85009.
https://doi.org/10.7554/eLife.85009

Share this article

https://doi.org/10.7554/eLife.85009

Further reading

    1. Immunology and Inflammation
    Zhiyan Wang, Nore Ojogun ... Mingfang Lu
    Research Article

    The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) has been increasing worldwide. Since gut-derived bacterial lipopolysaccharides (LPS) can travel via the portal vein to the liver and play an important role in producing hepatic pathology, it seemed possible that (1) LPS stimulates hepatic cells to accumulate lipid, and (2) inactivating LPS can be preventive. Acyloxyacyl hydrolase (AOAH), the eukaryotic lipase that inactivates LPS and oxidized phospholipids, is produced in the intestine, liver, and other organs. We fed mice either normal chow or a high-fat diet for 28 weeks and found that Aoah-/- mice accumulated more hepatic lipid than did Aoah+/+ mice. In young mice, before increased hepatic fat accumulation was observed, Aoah-/- mouse livers increased their abundance of sterol regulatory element-binding protein 1, and the expression of its target genes that promote fatty acid synthesis. Aoah-/- mice also increased hepatic expression of Cd36 and Fabp3, which mediate fatty acid uptake, and decreased expression of fatty acid-oxidation-related genes Acot2 and Ppara. Our results provide evidence that increasing AOAH abundance in the gut, bloodstream, and/or liver may be an effective strategy for preventing or treating MASLD.

    1. Cell Biology
    2. Immunology and Inflammation
    Alejandro Rosell, Agata Adelajda Krygowska ... Esther Castellano Sanchez
    Research Article

    Macrophages are crucial in the body’s inflammatory response, with tightly regulated functions for optimal immune system performance. Our study reveals that the RAS–p110α signalling pathway, known for its involvement in various biological processes and tumourigenesis, regulates two vital aspects of the inflammatory response in macrophages: the initial monocyte movement and later-stage lysosomal function. Disrupting this pathway, either in a mouse model or through drug intervention, hampers the inflammatory response, leading to delayed resolution and the development of more severe acute inflammatory reactions in live models. This discovery uncovers a previously unknown role of the p110α isoform in immune regulation within macrophages, offering insight into the complex mechanisms governing their function during inflammation and opening new avenues for modulating inflammatory responses.